Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antithrombotic efficacy of thrombin inhibitor L-374,087: intravenous activity in a primate model of venous thrombus extension and oral activity in a canine model of primary venous and coronary artery thrombosis.
Cook JJ, Gardell SJ, Holahan MA, Sitko GR, Stump GL, Wallace AA, Gilberto DB, Hare TR, Krueger JA, Dyer DL, Sanderson PE, Vacca JP, Shafer JA, Lynch JJ Jr. Cook JJ, et al. Among authors: sitko gr. J Pharmacol Exp Ther. 1999 Apr;289(1):503-10. J Pharmacol Exp Ther. 1999. PMID: 10087043
Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217.
Cook JJ, Holahan MA, Lyle EA, Ramjit DR, Sitko GR, Stranieri MT, Stupienski RF 3rd, Wallace AA, Hand EL, Gehret JR, Kothstein T, Drag MD, McCormick GY, Perkins JJ, Ihle NC, Duggan ME, Hartman GD, Gould RJ, Lynch JJ Jr. Cook JJ, et al. Among authors: sitko gr. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73. J Pharmacol Exp Ther. 1996. PMID: 8764336
Nonpeptide glycoprotein IIb/IIIa inhibitors. 15. Antithrombotic efficacy of L-738,167, a long-acting GPIIb/IIIa antagonist, correlates with inhibition of adenosine diphosphate-induced platelet aggregation but not with bleeding time prolongation.
Cook JJ, Sitko GR, Holahan MA, Stranieri MT, Glass JD, Askew BC, McIntyre CJ, Claremon DA, Baldwin JJ, Hartman GD, Gould RJ, Lynch JJ Jr. Cook JJ, et al. Among authors: sitko gr. J Pharmacol Exp Ther. 1997 May;281(2):677-89. J Pharmacol Exp Ther. 1997. PMID: 9152373
Metabolism-directed optimization of 3-aminopyrazinone acetamide thrombin inhibitors. Development of an orally bioavailable series containing P1 and P3 pyridines.
Burgey CS, Robinson KA, Lyle TA, Sanderson PE, Lewis SD, Lucas BJ, Krueger JA, Singh R, Miller-Stein C, White RB, Wong B, Lyle EA, Williams PD, Coburn CA, Dorsey BD, Barrow JC, Stranieri MT, Holahan MA, Sitko GR, Cook JJ, McMasters DR, McDonough CM, Sanders WM, Wallace AA, Clayton FC, Bohn D, Leonard YM, Detwiler TJ Jr, Lynch JJ Jr, Yan Y, Chen Z, Kuo L, Gardell SJ, Shafer JA, Vacca JP. Burgey CS, et al. Among authors: sitko gr. J Med Chem. 2003 Feb 13;46(4):461-73. doi: 10.1021/jm020311f. J Med Chem. 2003. PMID: 12570369
9-hydroxyazafluorenes and their use in thrombin inhibitors.
Stauffer KJ, Williams PD, Selnick HG, Nantermet PG, Newton CL, Homnick CF, Zrada MM, Lewis SD, Lucas BJ, Krueger JA, Pietrak BL, Lyle EA, Singh R, Miller-Stein C, White RB, Wong B, Wallace AA, Sitko GR, Cook JJ, Holahan MA, Stranieri-Michener M, Leonard YM, Lynch JJ Jr, McMasters DR, Yan Y. Stauffer KJ, et al. Among authors: sitko gr. J Med Chem. 2005 Apr 7;48(7):2282-93. doi: 10.1021/jm049423s. J Med Chem. 2005. PMID: 15801822
27 results